Moleculin Biotech, Inc. (MBRX) income statement
MBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$6.75−0.08 (-1.17%)
Close on Nov 18, 2026Market cap $131.47MP/E –Yield –
Moleculin Biotech, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -256.0%
Financial strength
- Current ratio
- 0.94
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 78.0%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 11.35
- Dividend yield
- –
See a number that looks wrong?